SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
760(Circulation. 2003;107:1308.) © 2003 American Heart Association, Inc. ---Miljenko Zuanic-3/10/2003
759Good review article. jci.org J. Clin. Invest. 111:565-570 (2003). doi:10.1172/Miljenko Zuanic-3/4/2003
758No question, market show very little optimism when obesity drug is an issue. UntMiljenko Zuanic-3/3/2003
757Drugmakers hope to win losing battle Companies persist in search for new obesityBiomaven-3/3/2003
756Press Release Source: Metabolic Pharmaceuticals Ltd Half a Kilo a Week - EarlyMiljenko Zuanic-3/2/2003
755Ashley, PEG-A went back to lab for reformulation. It will take 9-12 months beforMiljenko Zuanic-3/2/2003
754Regeneron's website notes they are working on "Pegylated AXOKINE is a A.J. Mullen-3/1/2003
753<<Conventional wisdom holds that an obesity therapy should be available inMiljenko Zuanic-2/28/2003
752Fat profits? Or fat chance? Regeneron aims to succeed where others have failed smh-2/28/2003
751Short interest at all time high. Last month increased by 20% or 1.4 millions shaMiljenko Zuanic-2/27/2003
750GY exercised 77,940 options (from 1995) and sold total 43,325, and increased posMiljenko Zuanic-2/26/2003
749JPM starts coverage at overweight and George Y files to sell 25,000.mopgcw-2/26/2003
748Is this good or bad for REGN? TIA.ocerg-2/22/2003
747Nature 421, 856 - 859 (2003); doi:10.1038/nature01388 STAT3 signalling is reMiljenko Zuanic-2/22/2003
746Interesting for IL-1 Trap, as it's action more effectively neutralize IL-1 (Miljenko Zuanic-2/17/2003
745That Kineret and Enbred do not synergy well is known from last RA conference. ItMiljenko Zuanic-2/12/2003
744Combining Anakinra and Etanercept Raises Infection Risk By Richard Woodman LONkeokalani'nui-2/12/2003
743RE: ML presentation. Nothing seriously new, but three note worth mentioning. 1Miljenko Zuanic-2/7/2003
742All what they reported is how good they are in spending and how quickly they areMiljenko Zuanic-1/30/2003
741Regeneron Reports Fourth Quarter and Full Year 2002 Financial and Operating Resumopgcw-1/30/2003
740No, I don't! :) Diabetes 52:252-259, 2003 © 2003 by the American DiabeMiljenko Zuanic-1/22/2003
739Stock price was over 50 in early 2000. Do you recall what factors drove it up? Maven1-1/18/2003
738Preparation for new finance round. Press Release Source: Regeneron PharmaceuticMiljenko Zuanic-1/17/2003
737They keep a selling. Neil Stahl sells 26,500 @ $18.62, ownership of 13,675mopgcw-1/10/2003
736OT <i>Last night and few past weeks I was occupied with few other things..quidditch-1/9/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News